CNBC Africa | Closing Bell
Stephen Saad | Zinathi Gquma
Commercial Pharmaceuticals’ double digit growth was highlighted as was the 40% contribution from Mounjaro. Global multinationals’ trust in Aspen was underscored with GLP-1 registrations across sub-Saharan Africa, notably Kenya and Nigeria.
Registration of Aspen’s generic GLP-1 injectable from Health Canada and pending registrations in Brazil as well as multiple other countries further validates Aspen’s Intellectual Property.
Business Day TV | News Leader
Stephen Saad | Ntaoleng Lechela
NHEPS is 28% higher on a constant currency basis while shareholders are being rewarded with a 10% rise in the dividend to R2,32. The robust demand for diabetes and weight loss drug Mounjaro boosted Aspen’s Commercial Pharmaceuticals division while Manufacturing enjoyed a good recovery. Aspen’s generic semaglutide GLP-1 has been registered in Canada with API awaited to enable rollout in that country. Registration of Aspen’s generic GLP-1 is also pending in Brazil, South Africa and as many as 20 emerging markets.
Newzroom Afrika | News@Prime
Sean Capazorio | Tumisang Ndlovu
The demand for diabetes and weight-management drug Mounjaro drove growth in Commercial Pharmaceuticals while a reshaped Manufacturing division delivered improved volumes.
The APAC divestment showed that the value of the sum of Aspen’s parts are much greater than the whole, with the net cash position being a highlight at year end off the back of a high debt position.
The GLP-1 market is currently valued at nearly R3bn in South Africa of which Mounjaro holds just over 50%. The local private sector enjoyed 40% growth which was driven by the GLP-1 demand.
702 | The Money Show | Cape Talk
Sean Capazorio | Stephen Grootes
Revenue in Commercial Pharmaceuticals was driven by the demand for Lilly’s Mounjaro which exceeded R1 billion and enjoys more than 50% of the local market. Pricing for generic semaglutide GLP-1s are expected to be at least half of the originator cost, which bodes well for further growth. Sterile manufacturing locally and in France is being reshaped with full 12-month benefits and volumes from Human Insulin products anticipated in the year ahead.
RSG | Geldsake
Sean Capazorio | Ryk van Niekerk
Aspen’s performance was aligned to market expectations and was underscored by the growth in Commercial Pharmaceuticals which was driven by the diabetes and weight-management drug, Lilly’s Mounjaro, which exceeded R1 billion in the financial year. Manufacturing’s guidance indicates profits more than doubly in the year ahead based on the reshaping and further organic growth anticipated from Commercial Pharmaceuticals.
Moneyweb | SAFM Market Update
Sean Capazorio | Jimmy Moyaha
Aspen delivered on all core priorities, reshaping the sterile manufacturing facilities with cost savings benefiting Manufacturing EBITDA. A good performance was recorded by Commercial Pharmaceuticals realising some 13% normalised profit growth. The benefit of strong free cashflow coupled with the APAC divestment placed Aspen in a nett cash position for the first time in the Group’s history.
GLP-1s are a big growth driver for Aspen through Lilly’s Mounjaro distribution agreement, with the product exceeding R1 billion in sales and claiming more than 50% of the market share.
Classic Business
Sean Capazorio | Michael Avery
Aspen reported a debt-free financial year with nett cash for the first time in the Group’s history and a strong guidance for the year ahead with EBITDA of at least R9 billion. Human Insulin contract volumes and additional volumes in Aspen’s French facility bode well for Manufacturing which is being reshaped while Commercial Pharmaceuticals stands to enjoy continued growth off the back of the demand for GLP-1s.
The capital structure is to continue to invest in the Group and to consider value enhancing projects were relevant as well as share buy-backs.
Moneyweb TV | The Executive Exchange
Stephen Saad | Bronwyn Nielsen
Stephen Saad joined Bronwyn Nielsen on Moneyweb TV’s flagship interview series The Executive Exchange to unpack his insightful and passionate leadership thinking, strategic decision‑making, and the forces influencing sustainable business growth in the challenging pharmaceutical sector in South Africa and internationally.
CNBC Africa | Closing Bell
Stephen Saad | Zinathi Gquma
Commercial Pharmaceuticals’ double digit growth was highlighted as was the 40% contribution from Mounjaro. Global multinationals’ trust in Aspen was underscored with GLP-1 registrations across sub-Saharan Africa, notably Kenya and Nigeria.
Registration of Aspen’s generic GLP-1 injectable from Health Canada and pending registrations in Brazil as well as multiple other countries further validates Aspen’s Intellectual Property.
Business Day TV | News Leader
Stephen Saad | Ntaoleng Lechela
NHEPS is 28% higher on a constant currency basis while shareholders are being rewarded with a 10% rise in the dividend to R2,32. The robust demand for diabetes and weight loss drug Mounjaro boosted Aspen’s Commercial Pharmaceuticals division while Manufacturing enjoyed a good recovery. Aspen’s generic semaglutide GLP-1 has been registered in Canada with API awaited to enable rollout in that country. Registration of Aspen’s generic GLP-1 is also pending in Brazil, South Africa and as many as 20 emerging markets.
Newzroom Afrika | News@Prime
Sean Capazorio | Tumisang Ndlovu
The demand for diabetes and weight-management drug Mounjaro drove growth in Commercial Pharmaceuticals while a reshaped Manufacturing division delivered improved volumes.
The APAC divestment showed that the value of the sum of Aspen’s parts are much greater than the whole, with the net cash position being a highlight at year end off the back of a high debt position.
The GLP-1 market is currently valued at nearly R3bn in South Africa of which Mounjaro holds just over 50%. The local private sector enjoyed 40% growth which was driven by the GLP-1 demand.
702 | The Money Show | Cape Talk
Sean Capazorio | Stephen Grootes
Revenue in Commercial Pharmaceuticals was driven by the demand for Lilly’s Mounjaro which exceeded R1 billion and enjoys more than 50% of the local market. Pricing for generic semaglutide GLP-1s are expected to be at least half of the originator cost, which bodes well for further growth. Sterile manufacturing locally and in France is being reshaped with full 12-month benefits and volumes from Human Insulin products anticipated in the year ahead.
RSG | Geldsake
Sean Capazorio | Ryk van Niekerk
Aspen’s performance was aligned to market expectations and was underscored by the growth in Commercial Pharmaceuticals which was driven by the diabetes and weight-management drug, Lilly’s Mounjaro, which exceeded R1 billion in the financial year. Manufacturing’s guidance indicates profits more than doubly in the year ahead based on the reshaping and further organic growth anticipated from Commercial Pharmaceuticals.
Moneyweb | SAFM Market Update
Sean Capazorio | Jimmy Moyaha
Aspen delivered on all core priorities, reshaping the sterile manufacturing facilities with cost savings benefiting Manufacturing EBITDA. A good performance was recorded by Commercial Pharmaceuticals realising some 13% normalised profit growth. The benefit of strong free cashflow coupled with the APAC divestment placed Aspen in a nett cash position for the first time in the Group’s history.
GLP-1s are a big growth driver for Aspen through Lilly’s Mounjaro distribution agreement, with the product exceeding R1 billion in sales and claiming more than 50% of the market share.
Classic Business
Sean Capazorio | Michael Avery
Aspen reported a debt-free financial year with nett cash for the first time in the Group’s history and a strong guidance for the year ahead with EBITDA of at least R9 billion. Human Insulin contract volumes and additional volumes in Aspen’s French facility bode well for Manufacturing which is being reshaped while Commercial Pharmaceuticals stands to enjoy continued growth off the back of the demand for GLP-1s.
The capital structure is to continue to invest in the Group and to consider value enhancing projects were relevant as well as share buy-backs.
Business Day TV | News Leader
Stavros Nicolaou | Zinathi Gquma
Aspen’s Stavros Nicolaou discussed the alarming global rise in non-communicable diseases, particularly diabetes, with Business Day TV’s Zinathi Gquma. He highlighted the importance of addressing Africa’s unmet need for diabetes treatment, encouraged citizens to be tested for the disease and to consult a healthcare professional if they are concerned about their health.
SABC | News
Stavros Nicolaou | Mfundo Mabalane
The notable global increase in NCDs, which are collectively responsible for 74% of deaths worldwide and include cardiovascular diseases, chronic respiratory disease, cancer and diabetes was discussed. This trend is being mirrored in South Africa where major NCDs have increased 58,7% over the past 20 years and it is set to continue along this trajectory.
Moneyweb | Hot 102.7
Stavros Nicolaou | Jeremy Maggs
Jeremy Maggs discussed the World Health Organisation’s declaration of diabetes as being a critical global health issue, and the impact of the disease which costs the global health sector approximately US$1trn. Stavros Nicolaou also highlighted the strong link between obesity, diabetes, and cancer, with the former triggering what has become known as the metabolic-cardio-renal complex of diseases
Power 98.7 | Power Business
Stavros Nicolaou | Nosipho Radebe
The alarming increase in non-communicable diseases, particularly Type II diabetes among adults and children, was highlighted in commemoration of World Diabetes Day. Stavros Nicolaou encouraged listeners to determine their diabetes status, seek appropriate treatment and consult with a healthcare professional about optimal management of this disease.
CNBC Africa | Closing Bell
Aspen’s operational performance was unpacked including action taken to pull back in Russia and China while growing the business. With more than 50% sterile capacity available, the single biggest opportunity relates to diabetic drugs with third-party manufacture and commercialisation agreements concluded for global supply outside the American and European markets.
Stephen Saad | Nastassia Arendse
Business Day TV | News Leader
Stephen Saad | Noluthando Mthonti-Mlambo
Growing the Commercial Pharmaceuticals business by 4% despite challenges in China and Russia was covered. Significant investments in Manufacturing and associated performance with 25% revenue growth contributed to a positive second half.
Newzroom Afrika | The Pulse
Stephen Saad | Tumisang Ndlovu
The pharmaceutical industry’s status post Covid was covered with Aspen’s investment in sterile manufacturing discussed. Weight loss and diabetes products offer significant opportunity and Aspen is actively pursuing. Equitable access to affordable diabetes and other products across Africa remains an imperative for the Group.
eNCA | Today | Business
Sean Capazorio | Thami Ngubeni
Strong performance from the Manufacturing business and a 4% revenue rise in Commercial Pharmaceuticals, supported by acquisitions, contributed to healthy growth notwithstanding the impact of the loss of sales in Russia and VBP in China. Growth in emerging market was underpinned by a range of acquisitions with full benefits expected to follow through in the next financial year.
702 and Cape Talk | The Money Show
Stephen Saad | Stephen Grootes
Aspen’s good news focuses on a derisked pharmaceutical base which offers double-digit growth prospects in the coming year. The manufacturing upside includes transfers in mRNA, insulins, vaccines, GLP-1s, as well as weight loss and obesity drugs opportunities for both the South African and French-based facilities.
RSG | Moneyweb
Stephen Saad | Ryk van Niekerk
Notwithstanding a R2 billion sales loss in Russia and China, Aspen grew Commercial Pharmaceuticals 4% with double-digit growth expected in the next year. Investment in sterile manufacturing capacity represents excellent opportunities.
Power987 | Power Business
Sean Capazorio | Noluthando Mthonti-Mlambo
Discussion of the strong top line growth was encouraging underpinned by the Manufacturing performance that grew 25%. As Aspen’s second largest region, strong growth is expected out of Latin America in FY25.
Moneyweb SAFM | Market Update
Sean Capazorio | Jimmy Moyaha
Strategic highlights and milestones were unpacked with discussion around Aspen’s highest normalised second half EBITDA and robust cash generation. The rapidly growing GLP-1 market is a key highlight for the Group going forward and this opportunity was also unpacked.
Fine Classic Business
Sean Capazorio | Michael Avery
Aspen’s solid performance was discussed after the Group’s pre-Covid restructuring which has resulted in a more focused and streamlined business with a balanced debt profile. Realising opportunities in the sterile sector and associated manufacturing prospects with an estimated 70% of medicines taking a sterile form by 2030 was also covered.
eNCA | South Africa Today
Stavros Nicolaou | Dan Moyane
Unpacking the African Vaccine Manufacturing Accelerator’s commitment to helping African countries achieve vaccine independence by producing 60% of their required vaccine doses by 2040.
SABC | The Agenda
Stavros Nicolaou | Mxolisi Masango
Accelerating vaccine access in Africa and the imperative of placing vaccine orders on Aspen and other local pharmaceutical manufacturers to ensure equitable access to critical healthcare treatment on the continent.
CNBC Africa | Closing Bell
Stavros Nicolaou | Tania Habimana
Aspen continues advocating for the local production of vaccines as South Africa’s healthcare system remains significantly challenged by the reliance of imported healthcare products. Currently less than 5% of medicines and less than 1% of vaccines are produced locally.
SABC | News
Stavros Nicolaou | Sophie Mokoena
Addressing the important topic of localising pharmaceutical and vaccine manufacture on the African continent to reduce healthcare inequality and improve health security.
Business Day TV | News Leader
Stavros Nicolaou | Zinathi Gquma
Africa’s initiatives to increase vaccine automony gains traction as the continent strives to reduce its dependency on some 80% of imported medicines and 99% of vaccines.
SABC Channel Africa
Stavros Nicolaou | Tracey Boomgaardt
Investigating ways in which Africa can reduce import dependency on medicines and vaccines and build regional and continental supply chain capacity to deliver equitable healthcare access.
Metro FM – News
Stavros Nicolaou | Zandile Hopa
SABC | Morning Live
Stavros Nicolaou | Donald Ramphadi
Aspen recently presented South African mobility impaired wheelchair tennis star Donald Ramphadi with a state-of-the-art high performance wheelchair ahead of his world tour. Donald has returned to the circuit to defend his French-open double quads title among others.
Read more here.
CNBC Africa | Closing Bell
Stephen Saad | Godfrey Mutizwa
Interim results were unpacked with insights provided on manufacturing opportunities from recently concluded contracts, the importance of mNRA technology and transformative prospects for the Group.
Business Day | The Close – News Leader
Stephen Saad | Ntaoleng Lechela
On the back of the 10% revenue increase, the interim numbers were contextualised with additional insights provided on growth prospects driven by contracts, the Heparin business, sterile manufacturing opportunities and the demand for obesity products.
eNCA: South Africa Tonight
Sean Capazorio | Melissa Tighy
Cashflow generation and trading operational performance was highlighted, together with sterile manufacturing investment which offers a strong growth curve from H2 through to FY2026 with acquisitions further augmenting growth.
Newzroom Afrika | The Pulse
Stephen Saad | Tumisang Ndlovu
Results highlights, with revenue growth and improved cash flow of 44%, came under discussion. Recent acquisitions will come to fruition complemented by Aspen’s R10 billion sterile manufacturing investment which will yield strong profit growth from H2 through FY2026.
SAFM Market Update and RSG
Stephen Saad | Tinus de Jager
Interim results, delivering on manufacturing contracts and implementation of the changed Heparin model was highlighted. Aspen’s R10 billion investment in sterile manufacturing is bearing fruit and the Group is well poised to leverage the global demand for obesity injectables with the production of Mounjaro which was secured through the recent agreement with Lilly. A strong second half is expect which will run through to FY2026.
702 The Money Show and Cape Talk Radio
Sean Capazorio | Bruce Whitfield
Bruce highlighted Aspen as being South Africa’s most global company, and he touched on contracts concluded which, as guided, will contribute an additional R4 billion. Aspen’s R10 billion manufacturing investment, mNRA technology, and the production of sterile, insulin, and paediatric vaccines for Africa also enjoyed attention.
Classic Business
Sean Capazorio | Michael Avery
The market’s positive response to Aspen’s results was highlighted. Tangible results from VBP impacts in China was discussed as well as exciting prospects in this territory. The Heparin business toll model transition, sterile manufacturing investment and strong revenue growth from Commercial Pharma and manufacturing enjoyed focus as did the prospect of additional contracts.
Power 98.7 | Power Business
Sean Capazorio | Nhlanhla Sehume
Transformative financial results and strategic shifts recently unveiled were highlighted. Collective initiatives, including the Heparin business toll model transition and the positive impact that this offers on cash flow, as well as a future sustainable business based on an efficient sterile manufacturing strategy complemented by ESG, additional acquisitions and other opportunities were discussed.
Newzroom Afrika
Stephen Saad | Xolani Mbanjwa
4 December 2023
The interview with Xolani Mbanjwa and Stephen Saad offered key insights into the Aspen | Sandoz announcement. Their discussion illuminated the strategic implications of the deal, emphasizing its impact on Aspen’s position in the pharmaceutical landscape and potential benefits for stakeholders.
eNCA: Night News
Sean Capazorio | Anlie Hattingh
5 December 2023
The eNCA Night News interview featuring Sean Capazorio and Anlie Hattingh provided a comprehensive exploration of key financial insights. Their discussion delved into market trends, offering viewers valuable perspectives on navigating the dynamic landscape of business and finance.
Business Day TV – News Leader
Sean Capazorio | Noluthando Mthonti-Mlambo
6 December 2023
Aspen and Sandoz have inked a near R2 billion deal. For that price tag, Aspen will buy Sandoz’s Chinese business. In return, Sandoz will take on four anaesthetic products that Aspen sells in Europe. Business Day TV unpacked the deal in greater details with Aspen’s Group CFO, Sean Capazorio.
CNBC Africa – Closing Bell
Sean Capazorio | Tania Habimana
7 December 2023
Sean Capazorio provided a high level understanding of the Sandoz agreements particularly the potential it offers for Aspen’s expansion in China given the acquisition of the full business from Sandoz in this territory. Deeper discussion touched on Aspen’s strong footprint in emerging markets with China being the Group’s beachhead in Asia.
Power 98.7: Power Business
Sean Capazorio | Noluthando Mthonti-Mlambo
4 December 2023
In the Power Business interview with Sean Capazorio and Noluthando Mthonti-Mlambo, dynamic insights emerged, outlining strategic visions for the energy sector. Their dialogue illuminated key trends, emphasizing sustainable practices and innovation in power management.
702: The Money Show
Sean Capazorio | Motheo Khoaripe
4 December 2023
The Money Show interview with Sean Capazorio and Motheo Khoaripe provided a compelling discussion on financial strategies and market trends. Their insights into investment and economic outlooks offered valuable perspectives for listeners navigating the ever-changing financial landscape.
SAfm Market Update – Moneyweb
Sean Capazorio | Jimmy Moyaha
7 December 2023
Sean Capazorio and Jimmy Moyaha discussed Aspen’s agreements with Sandoz as well as the Group’s recent announcements and opportunities for growth and diversification.
CNBC Africa: Closing Bell
Stephen Saad | Tania Habimana
The CNBC Closing Bell interview with Stephen Saad and Tania Habimana provided valuable insights into the impactful Novo Nordisk announcement, shedding light on its potential implications for the healthcare industry and global markets.
eNCA
Stephen Saad | Sally Burdett
The eNCA interview featuring Stephen Saad and Sally Burdett delved into the Aspen Novo Nordisk announcement, offering a comprehensive analysis of its significance within the pharmaceutical landscape and its potential ramifications for stakeholders worldwide.
702: The Money Show & Cape Talk Radio
Stavros Nicolaou | Bruce Whitfield
The Money Show with Bruce Whitfield and Stavros Nicolaou provided valuable insights into the Aspen-Novo Nordisk announcement, underscoring its significance in pharmaceutical collaboration. Their discussion shed light on the potential for healthcare advancements and business opportunities arising from this partnership.
702 Breakfast with Bongani Bingwa
Breakfast News Coverage
Bongani Bingwa’s Morning News on 702 delivered a comprehensive breakdown of the Novo Nordisk deal, emphasizing its impact on healthcare and the local economy.
Cape Talk 567
The Morning Review with Lester Kiewit
Cape Talk 567’s Morning News provided a thorough analysis of the Novo Nordisk deal, offering listeners a clear understanding of its implications for healthcare and the broader market.
CNBC Africa: Closing Bell
Stephen Saad | Tania Habimana
The CNBC Closing Bell interview with Stephen Saad and Tania Habimana showcased their visionary insights into healthcare and emerging markets, offering a compelling glimpse into the future of pharmaceuticals and sustainable business in Africa.
Newzroom Afrika
Stephen Saad | Xolani Mbanjwa
The Newzroom Afrika interview featuring Stephen Saad and Xolani Mbanjwa was a dynamic exchange of ideas, delving into critical topics shaping South Africa’s economy and healthcare sector, highlighting innovative solutions and future prospects.
eNCA: Moneydesk
Stephen Saad | Melissa Tighy
The eNCA Moneydesk interview with Stephen Saad and Melissa Tighy was an enlightening discussion on entrepreneurship, investment, and economic trends. Their insights provided valuable perspectives for viewers keen on financial success.
Business Day TV – The Close: News Leader
Stephen Saad | Zinathi Gquma
Business Day TV’s The Close, News Leader with Stephen Saad and Zinathi Gquma delivered an informative discussion on current market trends and business developments, shedding light on South Africa’s economic outlook with expertise and clarity.
702: The Money Show & Cape Talk Radio
Stephen Saad | Motheo Khoaripe
The Money Show with Motheo Khoaripe and Stephen Saad delivered a captivating dialogue on investment strategies and economic resilience. Their expertise and practical advice offered viewers valuable financial wisdom.
Moneyweb & RSG
Stephen Saad | Ryk van Niekerk
The Moneyweb and RSG interview featuring Stephen Saad and Ryk van Niekerk was a profound discussion, shedding light on investment strategies and economic trends. Their insights were a valuable resource for those looking to navigate the financial landscape effectively.
Power 98.7: Power Business
Sean Capazorio | Noluthando Mthonti-Mlambo
The Power 98.7 Power Business interview with Sean Capazorio and Noluthando Mthonti-Mlambo was an engaging exploration of business dynamics and innovation. Their insights offered a fresh perspective on success in the ever-evolving corporate world.
CNN Connecting Africa
Stephen Saad | Eleni Giokos
eNCA South Africa
Stavros Nicolaou | Devan Murguran
In a compelling interview on eNCA South Africa, Stavros Nicolaou and Devan Murguran engaged in an enlightening discussion. Their expert insights and thought-provoking dialogue shed light on the South African business landscape, offering viewers valuable perspectives on investment opportunities, challenges, and strategies for driving economic growth.
SABC News
SABC News featured an insightful conversation between Stavros Nicolaou and Katlego Legodi. The interview delved into key economic development, investment opportunities, and healthcare topics. Their exchange provided valuable insights, giving viewers a deeper understanding of the current business landscape and the potential for growth and innovation in South Africa.
Newzroom Afrika
Stavros Nicolaou | Ntokozo Khumalo
Newzroom Afrika conducted a thought-provoking interview with Stavros Nicolaou and Ntokozo Khumalo. The discussion covered various topics, including economic trends, investment prospects, and healthcare. Nicolaou’s expertise and Khumalo’s incisive questions gave viewers valuable insights into the South African business landscape and its implications for the country’s growth and development.
SaFM: Market Update for Moneyweb
Stavros Nicolaou | Fifi Peters
SaFM’s Market Update for Moneyweb featured a dynamic discussion between Stavros Nicolaou and Fifi Peters on the African Continental Free Trade Area Business Forum. The interview provided valuable insights on the forum’s outcomes, highlighting the potential for increased trade, collaboration, and economic growth in Africa.
SABC Channel Africa: Africa in Business
Stavros Nicolaou | Lulu Gaboo
SABC’s Africa in Business featured a discussion between Stavros Nicolaou and Lulu Gaboo on investment prospects, economic patterns, and healthcare in Africa. They offered insightful angles on promoting economic progress and establishing business growth throughout the continent.
SABC News
Stavros Nicolaou | Liabo Setho, Economics Reporter
SABC News Economics Reporter Liabo Setho engaged in an insightful conversation with Aspen’s Stavros Nicolaou at the highly anticipated 2023 South Africa Investment Conference. As energy challenges took centre stage during the event, the discussion shed light on Aspen’s perspective and strategies in addressing this critical issue.
eNCA
Stavros Nicolaou | Gareth Edwards
eNCA’s Gareth Edwards interviewed Stavros Nicolaou post the South Africa Investment Conference. The interview delved into various aspects of the conference, shedding light on the investment landscape in South Africa and the opportunities it presents. During the interview, Stavros Nicolaou, shared his perspectives on the investment climate in South Africa.
CNBC Africa
Stavros Nicolaou | Zanele Morrisson
CNBC’s Zanele Morrisson engaged in a compelling interview with Stavros Nicolaou at the South Africa Investment Conference, providing valuable insights into the country’s investment landscape. The interview delved into various topics, offering a comprehensive overview of the opportunities and challenges for investment in South Africa.
SaFM: Update at Noon
Stavros Nicolaou | Sakinna Kamwendo
In a recent episode of SaFM’s “Update at Noon,” host Sakinna Kamwendo conducted an engaging interview with Stavros Nicolaou. The interview provided listeners with valuable insights into the South African economy, investment trends, and strategies for driving growth.
eNCA’s “All Angles” featured a dynamic discussion between Stavros Nicolaou and Masego Rahlaga. The conversation delved into critical issues, offering a comprehensive view of the South African business landscape. Their insights provided valuable perspectives on economic growth, investment opportunities, and the future of various industries.
Stephen Saad and Zinathi Gquma had an engaging interview on Business Day TV’s News Leader segment. They discussed crucial business and economic matters, sharing valuable observations on industry patterns, investment techniques, and the financial forecast. It’s a must-watch for those seeking well-informed viewpoints on the business environment.
CNBC Africa
Stephen Saad | Tania Habimana
CNBC Africa hosted a discussion on business and economics with Stephen Saad and Tania Habimana. They talked about investment strategies, industry trends, and the African business landscape, offering valuable insights. Saad’s expertise and Habimana’s incisive questions provided clear understanding of key issues.
eNCA : South Africa Tonight
Stephen Saad | Sally Burdett
eNCA’s South Africa Tonight featured an interview with Stephen Saad and Sally Burdett on Aspen’s 2023 interim results, providing valuable insights into the company’s performance and achievements in a concise and informative manner.
Newzroom Afrika: NewsFeed
Stephen Saad | Xolani Mbanjwa
Newzroom Afrika’s NewsFeed featured Stephen Saad and Xolani Mbanjwa discussing Aspen’s 2023 interim results. The interview provided a concise overview of the company’s financial performance and future prospects, keeping viewers informed about Aspen’s latest developments.
The Nielsen Network: C-Suite
Stephen Saad | Bronwyn Nielsen
Stephen Saad and Bronwyn Nielsen discussed Aspen’s 2023 interim results on The Nielsen Network’s C-Suite. The interview offered a succinct overview of the company’s financial performance and strategic direction, providing valuable insights for viewers interested in Aspen’s progress.
The Money Show
Stephen Saad | Bruce Whitfield
On The Money Show, Stephen Saad and Bruce Whitfield analysed Aspen’s 2023 interim results, offering concise insights into the company’s financial performance and strategic outlook to keep listeners informed and engaged.
SAFM: Market Update
Sean Capazorio | Fifi Peters
SAFM’s Market Update covered Aspen’s 2023 interim results, with Sean Capazorio and Fifi Peters discussing the company’s financial status and future plans. The interview provided important insights for listeners.
Power 98.7: Power Business
Sean Capazorio | Jimmy Moyaha
Aspen’s interim results for 2023 were discussed on Power 98.7’s Power Business segment by Sean Capazorio and Jimmy Moyaha, providing valuable insights into the company’s financial performance and strategic outlook.
CNBC Africa
Stephen Saad | Godfrey Mutizwa
CNBC Africa’s Captains of Industry hosted an engaging conversation between Stephen Saad and Godfrey Mutizwa. The interview provided concise insights into business trends, investment strategies, and industry outlooks, offering valuable perspectives from these influential business leaders.
eNCA
Stavros Nicolaou | Tumelo Mothotoane
eNCA’s interview with Stavros Nicolaou and Tumelo Mothotoane on the earthquakes in Syria and Turkey was a poignant and informative discussion. The conversation explored the impact of the earthquakes on the affected regions, humanitarian efforts, and the importance of global collaboration in providing support and aid. Nicolaou and Mothotoane’s insights shed light on the challenges faced and the steps needed to help those affected rebuild their lives and communities.
Newzroom Afrika
Stavros Nicolaou | Xolani Mbanjwa
The Newzroom Afrika interview with Xolani Mbanjwa and Stavros Nicolaou delved into the Aspen-Gates-CEPI announcement, highlighting its global health impact. Their insights on vaccine access and production showcased a pivotal collaboration that aims to address pressing healthcare challenges on a broad scale.
702 and Cape Talk: The Money Show
Stavros Nicolaou | Bruce Whitfiled
The Money Show interview with Stavros Nicolaou and Bruce Whitfield provided a deep dive into the Aspen-Gates-CEPI announcement, unraveling its implications for global health and vaccine accessibility. Their discussion shed light on the collaborative efforts shaping a transformative response to healthcare challenges.
Moneyweb: Market Update
Stavros Nicolaou | Fifi Peters
The Moneyweb Market Update interview with Stavros Nicolaou and Fifi Peters delved into the Aspen-Gates-CEPI announcement, offering insights on its significance in global health and pharmaceutical advancements. Their discussion highlighted the collaborative efforts driving positive change in vaccine accessibility and production.
SAfm: Beyond the Headlines
Stavros Nicolaou | Aldrin Sampear
The SAfm: Beyond the Headlines interview with Stavros Nicolaou and Aldrin Sampear provided a nuanced exploration of the Aspen-Gates-CEPI announcement. Their discussion illuminated the strategic collaboration’s potential impact on vaccine equity and global health, contributing valuable insights to public discourse.
CNBC Africa
Sean Capazorio | Tania Habimana
Sean Capazorio and Tani Habimana discussed the EUR1.26 billion syndicated loan facilities, shedding light on strategic financial moves. Their insights emphasised Aspen’s financial strength and its ability to navigate global markets effectively.
Business Day TV: News Leader
Stephen Saad | Zinati Gquma
Zinati Gquma and Stephen Saad discussed Aspen’s impressive double-digit earnings growth. Their insights shed light on the factors driving the company’s success, providing valuable perspectives for investors and industry observers.
Newzroom Afrika
Stephen Saad | Xolani Mbanjwa
The Newzroom Afrika interview on August 31, 2022, featuring Xolani Mbanjwa and Stephen Saad, delved into critical business topics. Their discussion covered market dynamics, corporate strategies, and economic insights, offering viewers valuable perspectives on navigating the dynamic business landscape.
CNBC: The Closing Bell
Stephen Saad | Tania Habimana
Tania Habimana and Stephen Saad engaged in a insightful discussion. Their dialogue explored key financial trends, corporate strategies, and market dynamics, providing valuable insights for viewers navigating the evolving business landscape.
eNCA
Stephen Saad | Devan Murugan
This interview highlighted Aspen’s pivotal 10-year agreement with Serum Institute. Their discussion likely unveiled the strategic implications of this collaboration, emphasizing Aspen’s role in advancing pharmaceutical capabilities and global health initiatives.
The Nielsen Network’s C-Suite
Stephen Saad | Bronwyn Nielsen
On The Nielsen Network’s C-Suite, Bronwyn Nielsen and Stephen Saad engaged in a compelling discussion. Their dialogue likely provided valuable insights into business strategies, industry trends, and corporate leadership, contributing to a nuanced understanding of the evolving business landscape.
SABC News: Full View
Stavros Nicolaou | Francis Herd
Francis Herd and Stavros Nicolaou delved into critical healthcare discussions. Their dialogue likely covered pharmaceutical advancements, public health initiatives, and the broader impact of strategic collaborations, offering viewers insightful perspectives on the evolving medical landscape.
SABC News: Today & Reuters
News coverage
The Aspen and Serum Institute announcement took centre stage, revealing a transformative collaboration in the pharmaceutical realm. Insights shared likely highlighted the significance of this partnership in advancing global vaccine accessibility and production capabilities.
702 and Cape Talk: The Money Show
Stephen Saad | Bruce Whitfiled
Stephen Saad and Bruce Whitfield provided in-depth perspectives on pivotal topics in the business world. Their discussion likely covered market trends, company strategies, and economic outlooks, offering valuable insights for listeners navigating the dynamic financial landscape.
BBC World Radio: Focus on Africa
Lisa Bonadonna | Bola Mosuro
BBC World Radio’s Focus on Africa with Bola Mosuro and Dr Lisa Bonadonna explored critical health issues, providing insightful discussions on medical advancements and global health initiatives, and contributing to a nuanced understanding of healthcare challenges in Africa.
Newzroom Afrika
Lisa Bonadonna | Stephen Grootes
On Newzroom Afrika, Stephen Grootes and Dr. Lisa Bonadonna discussed Monkeypox vaccines, providing insights into research, development, and the global health impact. Their dialogue contributed to public awareness and understanding of efforts to combat emerging infectious diseases.
702 and Cape Talk: The Money Show
Lisa Bonadonna | Bruce Whitfield
On 702 & Cape Talk: The Money Show, Bruce Whitfield and Dr. Lisa Bonadonna discussed Aspen’s response to Monkeypox being declared a Public Health Emergency of International Concern by the WHO. Their insights addressed pharmaceutical strategies, global health implications, and Aspen’s role in combating infectious diseases.
SABC News: 2022 SA Investment Conference
Stavros Nicolaou | Peter Ndoro
Aspen’s recognition with the prestigious SAIC Business Award highlights its outstanding contributions to the business landscape. This accolade reflects Aspen’s commitment to excellence and innovation, solidifying its position as a leader in the industry.
SABC News: 2022 SA Investment Conference
Stavros Nicolaou | Glorious Sefako-Musi
Glorious Sefako-Musi and Stavros Nicolaou highlighted Aspen’s substantial investments in Gqeberha, South Africa, surpassing R8 billion. Their discussion underscored Aspen’s commitment to local development and economic growth, showcasing their significant impact on the region.
SABC News: The Globe
Stavros Nicolaou | Peter Ndoro
Peter Ndoro engaged with Stavros Nicolaou on Aspen’s second SAIC pledge of R500 million. Their conversation emphasised Aspen’s ongoing commitment to socio-economic development in South Africa, showcasing corporate responsibility and positive impact on community welfare.
CNBC Africa
Stavros Nicolaou | Fifi Peters
Fifi Peters and Stavros Nicolaou discussed Aspen’s impactful Covid-19 response, focusing on vaccine roll-out in Africa. Their dialogue highlighted Aspen’s crucial role in enhancing vaccine accessibility and addressing healthcare challenges on the continent.
Euronews: Focus
Stavros Nicolaou
In this EuroNews profile video for the 4th South Africa Investment Conference, Stavros Nicolaou showcases Aspen’s commitment to investment, innovation, and economic development, contributing to the country’s growth narrative and reinforcing the company’s pivotal role in South Africa’s business landscape.
eNCA
Stavros Nicolaou | Annika Larsen
Annika Larsen and Stavros Nicolaou highlighted Aspen’s impactful donation of medicines to Ukrainian patients. Their discussion emphasized the company’s commitment to global health and humanitarian efforts, showcasing Aspen’s corporate responsibility and positive contributions to international communities.
eNCA
Tumelo Mothotoane | Ms Liubov Abravitova
Tumelo Mothotoane and Ms. Liubov Abravitova, Ukraine Ambassador to SA, reflected on the Ukraine war one month later. Their discussion delved into the ongoing humanitarian situation, geopolitical implications, and international responses, providing viewers with critical insights into the evolving crisis.
eNCA
Stavros Nicolaou | Heidi Giokos
Stavros Nicolaou welcomed 10 South African students fleeing war-stricken Ukraine at OR Tambo International Airport. The coverage highlights Aspen’s support in facilitating their safe return, showcasing corporate responsibility during international crises.
eNCA
Stavros Nicolaou | Annika Larsen
Annika Larsen and Stavros Nicolaou highlighted Aspen’s pivotal role in repatriating 25 South African students from Ukraine. Their discussion underscored Aspen’s commitment to global responsibility, contributing to the well-being and safety of citizens during challenging times.
Times Live
Vutlhari Mtonga – SA Student
In the Times Live interview, Vutlhari Mtonga, a repatriated SA student from Ukraine, shared her experiences and made a heartfelt plea to aid Ukrainian citizens. Her account shed light on the human impact of the crisis, urging collective support for those affected.
Newzroom Afrika
Zikhona Tshona engaged with Stavros Nicolaou to discuss the repatriation of SA students from Ukraine. The dialogue underscored Aspen’s role in the humanitarian effort, highlighting collaborative initiatives during times of crisis.
Stavros Nicolaou | Zikhona Tshona
The Nielsen Network: C-Suite
Stephen Saad | Bronwyn Nielsen
Stephen Saad discussed Aspen’s financial performance, strategic initiatives, and the pharmaceutical landscape, offering key insights for investors and stakeholders.
Newzroom Afrika
Stephen Saad | Xolani Mbanjwa
Aspen’s significant deal with J&J to distribute COVID-19 vaccines across Africa and its interim results took centre stage. The discussion likely explored the strategic implications of the collaboration and provided insights into Aspen’s financial performance.
eNCA: South Africa Tonight
Stephen Saad | Devan Murugan
Devan Murugan engaged in a discussion on Aspen’s interim results with Stephen Saad. The dialogue provided valuable insights into the company’s financial performance and strategic outlook, contributing to a nuanced understanding of Aspen’s position in the pharmaceutical industry.
CNBC Africa – Closing Bell
Sean Capazorio | Godfrey Mutizwa
In a breaking news announcement on CNBC Africa, Godfrey Mutizwa shared new of Aspen’s significant Aspenovax announcement. This pivotal development shed light on Aspen’s innovative contributions to the global fight against COVID-19, impacting vaccine accessibility and public health.
CNBC Africa – Closing Bell
Sean Capazorio | Godfrey Mutizwa
Godfrey Mutizwa and Stephen Saad delved into Aspen’s interim results for 2021. Their discussion covered financial performance, market dynamics, and strategic initiatives, providing viewers with key insights into Aspen’s position and prospects in the pharmaceutical landscape.
The Nielsen Network: C-Suite
Stephen Saad | Bronwyn Nielsen
Stephen Saad discussed Aspen’s financial performance, strategic initiatives, and the pharmaceutical landscape, offering key insights for investors and stakeholders.
Newzroom Afrika
Stephen Saad | Xolani Mbanjwa
Aspen’s significant deal with J&J to distribute COVID-19 vaccines across Africa and its interim results took centre stage. The discussion likely explored the strategic implications of the collaboration and provided insights into Aspen’s financial performance.
eNCA: South Africa Tonight
Stephen Saad | Devan Murugan
Devan Murugan engaged in a discussion on Aspen’s interim results with Stephen Saad. The dialogue provided valuable insights into the company’s financial performance and strategic outlook, contributing to a nuanced understanding of Aspen’s position in the pharmaceutical industry.
CNBC Africa – Closing Bell
Sean Capazorio | Godfrey Mutizwa
In a breaking news announcement on CNBC Africa, Godfrey Mutizwa shared new of Aspen’s significant Aspenovax announcement. This pivotal development shed light on Aspen’s innovative contributions to the global fight against COVID-19, impacting vaccine accessibility and public health.
CNBC Africa – Closing Bell
Sean Capazorio | Godfrey Mutizwa
Godfrey Mutizwa and Stephen Saad delved into Aspen’s interim results for 2021. Their discussion covered financial performance, market dynamics, and strategic initiatives, providing viewers with key insights into Aspen’s position and prospects in the pharmaceutical landscape.
Aspen Media Briefing
Aspenovax Announcement
Aspen’s media briefing on the launch of Aspenovax showcased a pivotal moment in global health. The panel discussion highlighted the vaccine’s significance, emphasizing Aspen’s role in advancing accessibility and contributing to the fight against COVID-19.
CNN Live: Quest Means Business
Stephen Saad | Richard Quest
The live interview with Stephen Saad delved into the Aspen-J&J term sheet for Aspenovax. Their discussion provided insights into the strategic collaboration, emphasising its impact on vaccine production and global health efforts.
eNCA
Stephen Saad | Sally Burdett
Sally Burdett and Stephen Saad discussed the J&J term sheet for Aspenovax on November 30, 2021. The conversation explored the strategic implications of this collaboration, providing viewers with insights into Aspen’s role in advancing vaccine production.
The Nielsen Network: C-Suite – The Business of Money
Stephen Saad | Bronwyn Nielsen, Lindsay Williams & Anthony Clark
The Nielsen Network’s “The Business of Money” with Bronwyn Nielsen and Lindsay Williams, featuring Stephen Saad and Anthony Clark on “Strictly Business Podcasts,” provided valuable insights into finance and research. Their discussion covered key market trends, business strategies, and financial analysis, contributing to a comprehensive understanding of the dynamic economic landscape.
BBC World News
Stavros Nicolaou | Christian Fraser
Christian Fraser engaged with Stavros Nicolaou to discuss Aspenovax. The conversation highlighted the vaccine’s global impact and Aspen’s role in combating the COVID-19 pandemic, contributing to international awareness and understanding of vaccine development efforts.
Newzroom Afrika
Stephen Saad | Xolani Mbanjwa
The discussion with Aspen on the J&J term sheet for Aspenovax, highlighted the pivotal collaboration’s significance in advancing vaccine production and addressing critical healthcare needs amid the ongoing pandemic.
CNBC Closing Bell
Stavros Nicolaou | Godfrey Mutizwa
Godfrey Mutizwa and Stavros Nicolaou explored the significance of Aspenovax in the fight against COVID-19. Their discussion would have provided key insights into vaccine development and Aspen’s role in global health initiatives.
SABC News: The Globe
Stavros Nicolaou | Peter Ndoro
Peter Ndoro and Stavros Nicolaou discussed Aspenovax, shedding light on its global impact and Aspen’s pivotal role in vaccine development. This interview contributed to public awareness and understanding of ongoing efforts to combat the pandemic.
CGTV: Africa Live
Stavros Nicolaou | Julie Sheier
Julie Sheier and Stavros Nicolaou discussed Aspenovax, providing insights into its significance in Africa. Their conversation emphasised Aspen’s role in contributing to COVID-19 vaccine accessibility on the continent.
Vaccine Production Overview
Aspen’s Sterile manufacturing facility in Gqeberha, South Africa
Aspen’s state-of-the-art vaccine production facility in Gqeberha, South Africa, stands as a testament to the company’s commitment to advancing global health. Established in 2022, this cutting-edge facility represents a critical milestone in Aspen’s journey as a leading pharmaceutical manufacturer.
702 & Cape Talk: The Money Show
Stephen Saad | Bruce Whitfield
Bruce Whitfield and Stephen Saad discussed the non-binding term sheet between Aspen and Johnson & Johnson for Aspenovax. Their dialogue delved into strategic implications, showcasing Aspen’s pivotal role in advancing global vaccine production.
Podcast: Strictly Business
Stephen Saad | Lindsay Williams
Bruce Whitfield and Stephen Saad discussed the non-binding term sheet between Aspen and Johnson & Johnson for Aspenovax. Their dialogue delved into strategic implications, showcasing Aspen’s pivotal role in advancing global vaccine production.
SAfm Market Update: Moneyweb
Gus Attridge | Fifi Peters
Gus Attridge and Fifi Peters delved into the J&J-Aspen vaccine deal, shedding light on its implications. The interview provided valuable insights into the collaboration, emphasising Aspen’s role in advancing vaccine accessibility and global health initiatives.
Hot.fm: Hot Business
Gus Attridge | Michael Avery
Gus Attridge and Michael Avery discussed the deal, delving into its strategic impact. The interview provided insights into Aspen’s crucial role in bolstering vaccine production and contributing to global health efforts.
SAfm: Sunrise
Stavros Nicolaou | Stephen Grootes
Stavros Nicolaou and Stephen Grootes explored the J&J-Aspen vaccine deal, offering insights into its significance. The discussion emphasised Aspen’s pivotal role in advancing vaccine accessibility and global health initiatives.
Highlights Footage
Opening of Aspen’s general anaesthetics manufacturing line
The opening of Aspen’s General Anaesthetics Line in Gqeberha, South Africa, signifies a significant stride in pharmaceutical innovation. This state-of-the-art facility highlights Aspen’s commitment to medical advancements and reinforces its role as a key player in the global healthcare landscape.
Stephen Saad’s Address
Opening of Aspen’s general anaesthetics manufacturing line
Stephen Saad’s address emphasised the facility’s impact on healthcare, innovation, and Aspen’s dedication to advancing pharmaceutical manufacturing and medical solutions on a global scale.
Minister Ebrahim Patel’s Address
Opening of Aspen’s general anaesthetics manufacturing line
Minister Ebrahim Patel’s address highlighted the facility’s importance in advancing pharmaceutical manufacturing and fostering economic growth. His remarks emphasised the collaboration’s impact on job creation and medical innovation, underlining the government’s support for initiatives driving healthcare advancements in the country.
Ribbon Cutting and Plaque Unveiling
Opening of Aspen’s general anaesthetics manufacturing line
The ribbon-cutting and plaque unveiling at Aspen’s General Anaesthetics Line in Gqeberha, South Africa, marked a momentous occasion. This state-of-the-art facility underscores Aspen’s dedication to advancing healthcare, promoting innovation, and contributing to the region’s economic growth.
Newzroom Afrika: The Pulse
Sipha Kema reporting for Newzroom Afrika
During the tour of Aspen’s new facilities, the R3 billion investment showcased their commitment as Africa’s largest pharmaceutical company. This state-of-the-art facility reflects innovation and elevates Aspen’s pivotal role in healthcare.
SABC News
Kim Daniels reporting for SABC News
SABC News covered the inauguration of Aspen’s General Anaesthetics Line in Gqeberha, South Africa, emphasising its impact on local healthcare. The report highlighted Aspen’s contribution to the region’s medical advancements and economic growth.
eNCA
Stephen Saad | Govan Whittles
eNCA’s Govan Whittles reported live and discussed with Stephen Saad the opening of Aspen’s General Anaesthetics Line in Gqeberha, South Africa. The dialogue emphasised Aspen’s commitment to medical advancements and the positive impact on local and global healthcare.
Highlights Footage
Opening of Aspen’s general anaesthetics manufacturing line
The opening of Aspen’s General Anaesthetics Line in Gqeberha, South Africa, signifies a significant stride in pharmaceutical innovation. This state-of-the-art facility highlights Aspen’s commitment to medical advancements and reinforces its role as a key player in the global healthcare landscape.
Stephen Saad’s Address
Opening of Aspen’s general anaesthetics manufacturing line
Stephen Saad’s address emphasised the facility’s impact on healthcare, innovation, and Aspen’s dedication to advancing pharmaceutical manufacturing and medical solutions on a global scale.
Minister Ebrahim Patel’s Address
Opening of Aspen’s general anaesthetics manufacturing line
Minister Ebrahim Patel’s address highlighted the facility’s importance in advancing pharmaceutical manufacturing and fostering economic growth. His remarks emphasised the collaboration’s impact on job creation and medical innovation, underlining the government’s support for initiatives driving healthcare advancements in the country.
Ribbon Cutting and Plaque Unveiling
Opening of Aspen’s general anaesthetics manufacturing line
The ribbon-cutting and plaque unveiling at Aspen’s General Anaesthetics Line in Gqeberha, South Africa, marked a momentous occasion. This state-of-the-art facility underscores Aspen’s dedication to advancing healthcare, promoting innovation, and contributing to the region’s economic growth.
Newzroom Afrika: The Pulse
Sipha Kema reporting for Newzroom Afrika
During the tour of Aspen’s new facilities, the R3 billion investment showcased their commitment as Africa’s largest pharmaceutical company. This state-of-the-art facility reflects innovation and elevates Aspen’s pivotal role in healthcare.
SABC News
Kim Daniels reporting for SABC News
SABC News covered the inauguration of Aspen’s General Anaesthetics Line in Gqeberha, South Africa, emphasising its impact on local healthcare. The report highlighted Aspen’s contribution to the region’s medical advancements and economic growth.
eNCA
Stephen Saad | Govan Whittles
eNCA’s Govan Whittles reported live and discussed with Stephen Saad the opening of Aspen’s General Anaesthetics Line in Gqeberha, South Africa. The dialogue emphasised Aspen’s commitment to medical advancements and the positive impact on local and global healthcare.
eNCA: South Africa Tonight
Stephen Saad | Sally Burdett
26 July 2021
Aspen’s Chief Executive, Stephen Saad, discussed the J&J vaccine release with Sally Burdett. The interview provided insights into Aspen’s pivotal role in vaccine distribution, contributing to the global fight against COVID-19.
CNN: Live
Stephen Saad | Julia Chatterley
7 July 2021
In the CNN Live interview, Julia Chatterley and Aspen discussed the company’s investment in equitable vaccine access for Africa. The dialogue underscored Aspen’s commitment to fostering global health and ensuring widespread accessibility to life-saving vaccines on the continent.
Carte Blanche
Stephen Saad | Bongani Bingwa
25 April 2021
Bongani Bingwa discussed Aspen’s pivotal role in Covid vaccine production with Stephen Saad. Their dialogue highlighted the company’s commitment to global health and its significant contributions to the fight against the pandemic through vaccine manufacturing.
President Ramaphosa addresses the nation on COVID-19 response
30 March 2021
President Ramaphosa expresses gratitude to Aspen for their pivotal role in developing a COVID vaccine solution. The company’s contribution underscores a collaborative effort in safeguarding public health during the pandemic.
The Nielsen Network: C-Suite
Stephen Saad | Bronwyn Nielsen
30 March 2021
On the C-Suite Nielsen Network, Stephen Saad discussed Aspen’s role in the vaccine roll-out. His insights would have underscored the company’s commitment to global health, contributing to the success of vaccine distribution efforts.
SABC News: On Point
Stephen Saad | Nzinga Qunta
30 March 2021
On the C-Suite Nielsen Network, Stephen Saad discussed Aspen’s role in the vaccine roll-out. His insights would have underscored the company’s commitment to global health, contributing to the success of vaccine distribution efforts.
Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com
Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.